Weekly Recap | Revolution Medicines +0.81%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:37 AMRVMD+0.36%
Weekly Recap | Roche -4.04%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:34 AMRHHBY-0.19%
Weekly Recap | Lexicon Pharma +1.39%, consensus target above spotWeekly Review·Oct 3, 2026 at 07:11 AMLXRX0.00%
Weekly Recap | Eli Lilly -3.43%, most brokers rate it buyWeekly Review·Oct 3, 2026 at 07:08 AMLLY-0.61%LLYX-1.16%
Weekly Recap | Corcept Therap +0.11%, a choppy week ends higherWeekly Review·Oct 3, 2026 at 06:34 AMCORT+1.93%
Weekly Recap | Bristol Myers Squibb this week, a quiet, range-bound stretchWeekly Review·Oct 3, 2026 at 06:25 AMBMY+0.53%
Weekly Recap | XLV.US -2.65%, heavy pharma data but sector lagsWeekly Review·Oct 3, 2026 at 05:05 AMXLV-0.01%
Weekly Recap | VG Value -1.62%, trailing the S&P 500 by over a pointWeekly Review·Oct 3, 2026 at 05:03 AMVTV+0.24%
Weekly Recap | VG Health -2.41%, sector news heavy but price softWeekly Review·Oct 3, 2026 at 05:02 AMVHT+0.06%
Weekly Recap | DGRO.US -1.04%, defensive tilt lags the tapeWeekly Review·Oct 3, 2026 at 04:20 AMDGRO+0.44%
Weekly Recap | Vistagen Therap +13.75%, spike and fade after Phase 3 dataWeekly Review·Sep 26, 2026 at 07:18 AMVTGN-0.57%
